Share Price and Basic Stock Data
Last Updated: February 9, 2026, 10:12 pm
| PEG Ratio | -0.54 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dhampur Bio Organics Ltd operates in the sugar industry, with a current market capitalization of ₹675 Cr and a share price of ₹102. The company reported total sales of ₹2,408 Cr for the fiscal year ending March 2023, a significant increase from ₹1,564 Cr in March 2022. However, sales declined to ₹1,864 Cr in March 2024 and remained relatively stable at ₹1,862 Cr for March 2025. The trailing twelve months (TTM) sales stood at ₹2,012 Cr, indicating a decline from the previous fiscal year. Quarterly sales data shows fluctuations, with the highest quarterly sales of ₹803 Cr reported in March 2023, while sales dropped to ₹280 Cr in December 2023. Such volatility in revenue could be attributed to seasonal factors typical in the sugar sector, as well as varying demand dynamics. Overall, the revenue trajectory indicates a recovery potential, contingent on market conditions and operational efficiencies.
Profitability and Efficiency Metrics
In terms of profitability, Dhampur Bio Organics reported a net profit of ₹111 Cr in March 2023, which decreased to ₹46 Cr in March 2024 and further declined to ₹15 Cr in March 2025. The operating profit margin (OPM) reflected a downward trend, recording 8% in March 2023, falling to 7% in March 2025. The company’s return on equity (ROE) stood at a modest 1.56%, while the return on capital employed (ROCE) was recorded at 3.97%. The cash conversion cycle (CCC) was reported at 270 days, indicating potential inefficiencies in inventory management and receivables collection, particularly when compared to industry averages. Additionally, the interest coverage ratio (ICR) of 2.06x suggests that while the company can meet its interest obligations, its ability to generate profit before tax is limited. The profitability metrics signal a need for operational improvements to enhance margins and returns.
Balance Sheet Strength and Financial Ratios
Dhampur Bio Organics’ balance sheet shows total assets of ₹1,645 Cr as of September 2025, with total liabilities at ₹1,645 Cr, indicating a balanced financial structure. The company reported reserves of ₹895 Cr and borrowings of ₹562 Cr, resulting in a debt-to-equity ratio of 0.23, which is relatively low and suggests prudent financial management. The price-to-book value (P/BV) ratio stood at 0.43x, indicating that the stock may be undervalued compared to its book value. However, the current ratio of 1.14x suggests that while the company can meet its short-term liabilities, liquidity may be tight. Moreover, the interest coverage ratio of 2.06x indicates that while the company can cover its interest expenses, the margin for error is slim. These figures highlight strengths in capital structure but also raise concerns regarding liquidity and operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dhampur Bio Organics reflects a significant promoter holding of 50.65%, which provides stability and confidence in management. However, foreign institutional investors (FIIs) have reduced their stake from 6.63% in December 2022 to 0.35% by September 2025, indicating waning interest from foreign investors. Domestic institutional investors (DIIs) have also maintained a minimal presence at 0.45%, while public shareholding accounts for 47.67%. The total number of shareholders has decreased to 48,055, suggesting possible shareholder attrition amid fluctuating performance. This pattern indicates a lack of confidence from institutional investors, which could impact liquidity and market perception. A robust promoter stake can mitigate some risks, but the declining FII interest raises questions about the company’s attractiveness to broader investor segments.
Outlook, Risks, and Final Insight
Looking ahead, Dhampur Bio Organics faces both opportunities and challenges. The company’s strengths include a solid promoter backing, a relatively low debt level, and potential for revenue recovery as market conditions stabilize. However, significant risks exist, including fluctuating sales trends, declining profitability margins, and the potential for increased competition in the sugar sector. The company’s operational inefficiencies, as indicated by a high cash conversion cycle, could further hamper profitability if not addressed. The ability to enhance operational efficiency and manage costs will be critical in navigating these challenges. As the company seeks to improve its financial performance, strategic initiatives focused on enhancing production efficiency and expanding market reach could prove beneficial in the evolving sugar landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gayatri Sugars Ltd | 75.6 Cr. | 10.2 | 16.7/7.02 | 270 | 16.8 | 0.00 % | 36.6 % | % | 10.0 |
| Dhampure Speciality Sugars Ltd | 83.7 Cr. | 95.8 | 115/82.0 | 21.2 | 45.3 | 0.00 % | 11.6 % | 8.88 % | 10.0 |
| Dhampur Bio Organics Ltd | 657 Cr. | 99.3 | 115/57.3 | 27.7 | 145 | 1.26 % | 3.97 % | 1.56 % | 10.0 |
| DCM Shriram Industries Ltd | 525 Cr. | 40.3 | 63.1/36.0 | 8.62 | 105 | 4.96 % | 13.7 % | 11.8 % | 2.00 |
| Davangere Sugar Company Ltd | 639 Cr. | 4.46 | 11.0/3.03 | 50.6 | 3.52 | 0.00 % | 6.70 % | 3.17 % | 1.00 |
| Industry Average | 1,721.59 Cr | 254.04 | 29.61 | 225.56 | 0.84% | 8.62% | 7.89% | 6.37 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 594 | 803 | 583 | 538 | 280 | 463 | 467 | 466 | 464 | 464 | 526 | 558 | 486 |
| Expenses | 559 | 687 | 543 | 519 | 284 | 382 | 434 | 476 | 448 | 369 | 524 | 566 | 444 |
| Operating Profit | 34 | 116 | 41 | 19 | -4 | 81 | 33 | -10 | 16 | 96 | 1 | -8 | 43 |
| OPM % | 6% | 14% | 7% | 4% | -2% | 18% | 7% | -2% | 3% | 21% | 0% | -1% | 9% |
| Other Income | 1 | 2 | 2 | 1 | 16 | 5 | 1 | 1 | -1 | 1 | 2 | 13 | 9 |
| Interest | 5 | 13 | 13 | 9 | 6 | 18 | 21 | 16 | 10 | 20 | 22 | 14 | 11 |
| Depreciation | 10 | 13 | 11 | 10 | 14 | 14 | 12 | 11 | 15 | 16 | 14 | 15 | 15 |
| Profit before tax | 20 | 92 | 18 | 0 | -8 | 54 | 1 | -35 | -10 | 61 | -33 | -23 | 26 |
| Tax % | 26% | 13% | 32% | 88% | -28% | 28% | 83% | -34% | -32% | 26% | -33% | -32% | 34% |
| Net Profit | 15 | 80 | 13 | 0 | -6 | 39 | 0 | -23 | -7 | 45 | -22 | -16 | 17 |
| EPS in Rs | 2.26 | 12.08 | 1.91 | 0.01 | -0.85 | 5.94 | 0.02 | -3.52 | -1.03 | 6.75 | -3.31 | -2.41 | 2.55 |
Last Updated: February 2, 2026, 7:46 am
Below is a detailed analysis of the quarterly data for Dhampur Bio Organics Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 486.00 Cr.. The value appears to be declining and may need further review. It has decreased from 558.00 Cr. (Sep 2025) to 486.00 Cr., marking a decrease of 72.00 Cr..
- For Expenses, as of Dec 2025, the value is 444.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 566.00 Cr. (Sep 2025) to 444.00 Cr., marking a decrease of 122.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 43.00 Cr.. The value appears strong and on an upward trend. It has increased from -8.00 Cr. (Sep 2025) to 43.00 Cr., marking an increase of 51.00 Cr..
- For OPM %, as of Dec 2025, the value is 9.00%. The value appears strong and on an upward trend. It has increased from -1.00% (Sep 2025) to 9.00%, marking an increase of 10.00%.
- For Other Income, as of Dec 2025, the value is 9.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Sep 2025) to 9.00 Cr., marking a decrease of 4.00 Cr..
- For Interest, as of Dec 2025, the value is 11.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 14.00 Cr. (Sep 2025) to 11.00 Cr., marking a decrease of 3.00 Cr..
- For Depreciation, as of Dec 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 15.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from -23.00 Cr. (Sep 2025) to 26.00 Cr., marking an increase of 49.00 Cr..
- For Tax %, as of Dec 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from -32.00% (Sep 2025) to 34.00%, marking an increase of 66.00%.
- For Net Profit, as of Dec 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from -16.00 Cr. (Sep 2025) to 17.00 Cr., marking an increase of 33.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 2.55. The value appears strong and on an upward trend. It has increased from -2.41 (Sep 2025) to 2.55, marking an increase of 4.96.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:52 am
| Metric | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|
| Sales | 0 | 1,564 | 2,408 | 1,864 | 1,862 | 2,012 |
| Expenses | 0 | 1,381 | 2,203 | 1,724 | 1,727 | 1,907 |
| Operating Profit | -0 | 183 | 205 | 140 | 135 | 105 |
| OPM % | 12% | 8% | 8% | 7% | 5% | |
| Other Income | 0 | 8 | 11 | 20 | 2 | 15 |
| Interest | 0 | 30 | 41 | 45 | 67 | 66 |
| Depreciation | 0 | 31 | 41 | 49 | 54 | 60 |
| Profit before tax | -0 | 129 | 135 | 65 | 16 | -6 |
| Tax % | 0% | 21% | 18% | 29% | 6% | |
| Net Profit | -0 | 102 | 111 | 46 | 15 | -0 |
| EPS in Rs | 16.74 | 7.00 | 2.21 | -0.00 | ||
| Dividend Payout % | 0% | 0% | 21% | 36% | 56% |
YoY Net Profit Growth
| Year | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | 8.82% | -58.56% | -67.39% |
| Change in YoY Net Profit Growth (%) | 0.00% | -67.38% | -8.83% |
Dhampur Bio Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -46% |
| TTM: | -117% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -38% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 6% |
| Last Year: | 2% |
Last Updated: September 5, 2025, 3:11 pm
Balance Sheet
Last Updated: December 4, 2025, 2:44 am
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 66 | 66 | 66 | 66 | 66 | 66 |
| Reserves | 709 | 812 | 922 | 945 | 945 | 895 |
| Borrowings | 403 | 835 | 810 | 1,057 | 1,162 | 562 |
| Other Liabilities | 373 | 287 | 278 | 244 | 223 | 121 |
| Total Liabilities | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 | 1,645 |
| Fixed Assets | 631 | 690 | 909 | 1,036 | 1,076 | 1,136 |
| CWIP | 7 | 78 | 36 | 13 | 79 | 8 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 |
| Other Assets | 913 | 1,232 | 1,132 | 1,263 | 1,242 | 498 |
| Total Assets | 1,551 | 2,000 | 2,077 | 2,313 | 2,398 | 1,645 |
Below is a detailed analysis of the balance sheet data for Dhampur Bio Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 66.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 66.00 Cr..
- For Reserves, as of Sep 2025, the value is 895.00 Cr.. The value appears to be declining and may need further review. It has decreased from 945.00 Cr. (Mar 2025) to 895.00 Cr., marking a decrease of 50.00 Cr..
- For Borrowings, as of Sep 2025, the value is 562.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 1,162.00 Cr. (Mar 2025) to 562.00 Cr., marking a decrease of 600.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 121.00 Cr.. The value appears to be improving (decreasing). It has decreased from 223.00 Cr. (Mar 2025) to 121.00 Cr., marking a decrease of 102.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,645.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,398.00 Cr. (Mar 2025) to 1,645.00 Cr., marking a decrease of 753.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,136.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,076.00 Cr. (Mar 2025) to 1,136.00 Cr., marking an increase of 60.00 Cr..
- For CWIP, as of Sep 2025, the value is 8.00 Cr.. The value appears to be declining and may need further review. It has decreased from 79.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 71.00 Cr..
- For Investments, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 498.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,242.00 Cr. (Mar 2025) to 498.00 Cr., marking a decrease of 744.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,645.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,398.00 Cr. (Mar 2025) to 1,645.00 Cr., marking a decrease of 753.00 Cr..
Notably, the Reserves (895.00 Cr.) exceed the Borrowings (562.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Free Cash Flow | -403.00 | -652.00 | -605.00 | 139.00 | 134.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debtor Days | 25 | 23 | 17 | 11 | |
| Inventory Days | 341 | 163 | 288 | 288 | |
| Days Payable | 54 | 33 | 37 | 29 | |
| Cash Conversion Cycle | 312 | 154 | 269 | 270 | |
| Working Capital Days | 56 | 24 | 33 | 21 | |
| ROCE % | 11% | 10% | 5% | 4% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Diluted EPS (Rs.) | 2.21 | 7.00 | 16.74 | 15.35 | 0.00 |
| Cash EPS (Rs.) | 10.33 | 14.46 | 22.84 | 20.06 | 0.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 152.39 | 152.35 | 148.93 | 132.16 | 116.73 |
| Revenue From Operations / Share (Rs.) | 280.39 | 280.83 | 362.63 | 232.10 | 0.00 |
| PBDIT / Share (Rs.) | 20.86 | 24.15 | 32.56 | 28.68 | 0.00 |
| PBIT / Share (Rs.) | 12.74 | 16.69 | 26.45 | 23.96 | 0.00 |
| PBT / Share (Rs.) | 2.37 | 9.86 | 20.30 | 19.43 | 0.00 |
| Net Profit / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| NP After MI And SOA / Share (Rs.) | 2.21 | 7.00 | 16.73 | 15.35 | 0.00 |
| PBDIT Margin (%) | 7.43 | 8.59 | 8.97 | 12.35 | 0.00 |
| PBIT Margin (%) | 4.54 | 5.94 | 7.29 | 10.32 | 0.00 |
| PBT Margin (%) | 0.84 | 3.51 | 5.59 | 8.36 | 0.00 |
| Net Profit Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| NP After MI And SOA Margin (%) | 0.78 | 2.49 | 4.61 | 6.61 | 0.00 |
| Return on Networth / Equity (%) | 1.45 | 4.59 | 11.23 | 11.61 | 0.00 |
| Return on Capital Employeed (%) | 6.42 | 8.78 | 14.41 | 15.23 | 0.00 |
| Return On Assets (%) | 0.61 | 2.01 | 5.34 | 5.09 | 0.00 |
| Long Term Debt / Equity (X) | 0.23 | 0.17 | 0.17 | 0.11 | 0.12 |
| Total Debt / Equity (X) | 1.14 | 1.03 | 0.81 | 0.93 | 0.50 |
| Asset Turnover Ratio (%) | 0.79 | 0.84 | 1.18 | 0.86 | 0.00 |
| Current Ratio (X) | 1.14 | 1.19 | 1.31 | 1.28 | 1.46 |
| Quick Ratio (X) | 0.12 | 0.16 | 0.35 | 0.17 | 0.29 |
| Inventory Turnover Ratio (X) | 1.71 | 1.69 | 1.69 | 1.62 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 113.00 | 49.96 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 24.20 | 24.20 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -13.00 | 50.04 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 75.80 | 75.80 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.06 | 3.54 | 5.29 | 6.32 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 1.25 | 2.03 | 3.72 | 4.38 | 0.00 |
| Enterprise Value (Cr.) | 1553.77 | 1776.49 | 1647.22 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.83 | 0.95 | 0.68 | 0.00 | 0.00 |
| EV / EBITDA (X) | 11.22 | 11.08 | 7.62 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| Retention Ratios (%) | -13.00 | 50.03 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 0.43 | 0.75 | 0.96 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.23 | 0.40 | 0.39 | 0.00 | 0.00 |
| EarningsYield | 0.03 | 0.06 | 0.11 | 0.00 | 0.00 |
After reviewing the key financial ratios for Dhampur Bio Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 5. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.33. This value is within the healthy range. It has decreased from 14.46 (Mar 24) to 10.33, marking a decrease of 4.13.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 152.39. It has increased from 152.35 (Mar 24) to 152.39, marking an increase of 0.04.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 280.39. It has decreased from 280.83 (Mar 24) to 280.39, marking a decrease of 0.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 20.86. This value is within the healthy range. It has decreased from 24.15 (Mar 24) to 20.86, marking a decrease of 3.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.74. This value is within the healthy range. It has decreased from 16.69 (Mar 24) to 12.74, marking a decrease of 3.95.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.37. This value is within the healthy range. It has decreased from 9.86 (Mar 24) to 2.37, marking a decrease of 7.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 7.00 (Mar 24) to 2.21, marking a decrease of 4.79.
- For PBDIT Margin (%), as of Mar 25, the value is 7.43. This value is below the healthy minimum of 10. It has decreased from 8.59 (Mar 24) to 7.43, marking a decrease of 1.16.
- For PBIT Margin (%), as of Mar 25, the value is 4.54. This value is below the healthy minimum of 10. It has decreased from 5.94 (Mar 24) to 4.54, marking a decrease of 1.40.
- For PBT Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 10. It has decreased from 3.51 (Mar 24) to 0.84, marking a decrease of 2.67.
- For Net Profit Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 5. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 8. It has decreased from 2.49 (Mar 24) to 0.78, marking a decrease of 1.71.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has decreased from 4.59 (Mar 24) to 1.45, marking a decrease of 3.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 8.78 (Mar 24) to 6.42, marking a decrease of 2.36.
- For Return On Assets (%), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 2.01 (Mar 24) to 0.61, marking a decrease of 1.40.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has increased from 0.17 (Mar 24) to 0.23, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.14. This value exceeds the healthy maximum of 1. It has increased from 1.03 (Mar 24) to 1.14, marking an increase of 0.11.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.79. It has decreased from 0.84 (Mar 24) to 0.79, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 1.5. It has decreased from 1.19 (Mar 24) to 1.14, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.16 (Mar 24) to 0.12, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 4. It has increased from 1.69 (Mar 24) to 1.71, marking an increase of 0.02.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 113.00. This value exceeds the healthy maximum of 50. It has increased from 49.96 (Mar 24) to 113.00, marking an increase of 63.04.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 24.20. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 24.20.
- For Earning Retention Ratio (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 40. It has decreased from 50.04 (Mar 24) to -13.00, marking a decrease of 63.04.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 75.80. This value exceeds the healthy maximum of 70. There is no change compared to the previous period (Mar 24) which recorded 75.80.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.06. This value is below the healthy minimum of 3. It has decreased from 3.54 (Mar 24) to 2.06, marking a decrease of 1.48.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.25. This value is below the healthy minimum of 3. It has decreased from 2.03 (Mar 24) to 1.25, marking a decrease of 0.78.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,553.77. It has decreased from 1,776.49 (Mar 24) to 1,553.77, marking a decrease of 222.72.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 0.95 (Mar 24) to 0.83, marking a decrease of 0.12.
- For EV / EBITDA (X), as of Mar 25, the value is 11.22. This value is within the healthy range. It has increased from 11.08 (Mar 24) to 11.22, marking an increase of 0.14.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For Retention Ratios (%), as of Mar 25, the value is -13.00. This value is below the healthy minimum of 30. It has decreased from 50.03 (Mar 24) to -13.00, marking a decrease of 63.03.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.75 (Mar 24) to 0.43, marking a decrease of 0.32.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 1. It has decreased from 0.40 (Mar 24) to 0.23, marking a decrease of 0.17.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.03, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhampur Bio Organics Ltd:
- Net Profit Margin: 0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.42% (Industry Average ROCE: 8.62%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 7.89%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.25
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 27.7 (Industry average Stock P/E: 29.61)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.78%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Sugar | Sugar Mill Compound, Village & Post - Asmoli, Sambhal Dist. Uttar Pradesh 244304 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Vijay Kumar Goel | Chairman |
| Mr. Ashwani Kumar Gupta | Vice Chairman |
| Mr. Gautam Goel | Managing Director & CEO |
| Mr. Sandeep Kumar | Whole Time Director |
| Mrs. Bindu Vashist Goel | Non Executive Director |
| Mrs. Ruchika Amrish Mehra Kothari | Independent Director |
| Mr. Vishal Saluja | Independent Director |
| Mr. Samir Thukral | Independent Director |
| Mr. Kishor Shah | Independent Director |
FAQ
What is the intrinsic value of Dhampur Bio Organics Ltd?
Dhampur Bio Organics Ltd's intrinsic value (as of 09 February 2026) is ₹24.73 which is 75.10% lower the current market price of ₹99.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹657 Cr. market cap, FY2025-2026 high/low of ₹115/57.3, reserves of ₹895 Cr, and liabilities of ₹1,645 Cr.
What is the Market Cap of Dhampur Bio Organics Ltd?
The Market Cap of Dhampur Bio Organics Ltd is 657 Cr..
What is the current Stock Price of Dhampur Bio Organics Ltd as on 09 February 2026?
The current stock price of Dhampur Bio Organics Ltd as on 09 February 2026 is ₹99.3.
What is the High / Low of Dhampur Bio Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dhampur Bio Organics Ltd stocks is ₹115/57.3.
What is the Stock P/E of Dhampur Bio Organics Ltd?
The Stock P/E of Dhampur Bio Organics Ltd is 27.7.
What is the Book Value of Dhampur Bio Organics Ltd?
The Book Value of Dhampur Bio Organics Ltd is 145.
What is the Dividend Yield of Dhampur Bio Organics Ltd?
The Dividend Yield of Dhampur Bio Organics Ltd is 1.26 %.
What is the ROCE of Dhampur Bio Organics Ltd?
The ROCE of Dhampur Bio Organics Ltd is 3.97 %.
What is the ROE of Dhampur Bio Organics Ltd?
The ROE of Dhampur Bio Organics Ltd is 1.56 %.
What is the Face Value of Dhampur Bio Organics Ltd?
The Face Value of Dhampur Bio Organics Ltd is 10.0.